Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
Blood and Nerve Supply to the Kidney01:18

Blood and Nerve Supply to the Kidney

5.7K
The kidneys are vital organs responsible for filtering and cleaning blood, removing waste products, and regulating electrolyte levels. To perform these essential functions, they require a constant and robust blood supply.
Bloody Supply to the Kidneys:
The kidneys receive their blood supply from the renal arteries, which branch off from the abdominal aorta—the main artery supplying the abdomen and lower body. The renal arteries enter the kidneys at the hilum, a notch on the medial side of...
5.7K
Imaging Studies VII: Vascular Imaging01:19

Imaging Studies VII: Vascular Imaging

474
DefinitionRenal angiography, also known as renal arteriography, is an imaging technique used to obtain a comprehensive view of blood flow and the vascular structure of blood vessels in the kidneys and surrounding areas.PurposeRenal angiography detects blood vessel abnormalities in the kidneys, such as aneurysms, stenosis, thrombosis, vascular tumors, and renal artery stenosis. It evaluates kidney function and guides interventional treatments like angioplasty or stent placement.Pre-Procedure...
474
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.7K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trajectories of depressive symptoms across pregnancy and the extended postpartum period and future cardiovascular health.

medRxiv : the preprint server for health sciences·2026
Same author

Forgotten Gangliosides: <i>O</i>-Acetylated and Lactone Gangliosides.

International journal of molecular sciences·2026
Same author

Neurotrophic Modulation Restores Motor and Developmental Defects in Zebrafish Models of ints11 Deficiency.

Journal of neurochemistry·2026
Same author

Is Stable CAD the Same in All Circumstances? The Curious Case of PCI Before TAVR.

Circulation. Cardiovascular interventions·2026
Same author

Editorial commentary: Parkinson's disease and cardiovascular disease: A complex combination of clinical conundrums.

Trends in cardiovascular medicine·2026
Same author

The Involvement of Ceramide, Sphingosine-1-Phosphate and Ganglioside GM1 in Regulating Some Nervous System Functions.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Mar 31, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K

Renal Denervation: Where to Now?

Neil J Wimmer1,2, Laura Mauri3

  • 1Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02132, USA. neil.j.wimmer@christianacare.org.

Current Cardiology Reports
|October 21, 2015
PubMed
Summary

Resistant hypertension is a global issue. Renal sympathetic denervation showed early promise but failed to demonstrate benefits in a key trial, requiring further research into its role in hypertension treatment.

Keywords:
HypertensionRandomized clinical trialRenal denervation

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

862
Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats
06:30

Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

Published on: September 11, 2018

8.4K

Related Experiment Videos

Last Updated: Mar 31, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

862
Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats
06:30

Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

Published on: September 11, 2018

8.4K

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Nephrology

Background:

  • Resistant hypertension affects a growing number of patients globally.
  • Renal sympathetic denervation (RSD) emerged as a potential treatment for resistant hypertension.
  • Early studies suggested significant benefits of RSD, but later trials yielded conflicting results.

Purpose of the Study:

  • To evaluate the efficacy of renal sympathetic denervation in treating resistant hypertension.
  • To understand the current status and future potential of RSD in hypertension management.

Main Methods:

  • Review of early studies and the pivotal SYMPLICITY 3-HTN trial.
  • Discussion of the physiological and anatomical aspects of renal sympathetic pathways.
  • Consideration of medication adherence in hypertensive patients.

Main Results:

  • The SYMPLICITY 3-HTN trial, a randomized sham-controlled study, did not show a benefit of RSD compared to sham treatment.
  • Conflicting results highlight the need for further investigation.

Conclusions:

  • Further research is needed to understand the role of renal sympathetic denervation in hypertension.
  • Continued evaluation of RSD technology is expected in various disease states.
  • RSD technology remains available clinically outside the USA, with anticipated future developments.